Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Newsletter 2023

Newsletter January 2023: Case report: Successful management of “Stiff Person Syndrome” patient for day care procedure

Kean Seng Cheah, MBBS, FCAI

Case description:
Stiff person syndrome is a rare autoimmune neurological syndrome that manifests as fluctuating rigidity and spasms of axial or limb muscles¹. This condition was first described in 1956 by Moersch & Woltman from a case series of 14 patients with a similar presentation of muscle rigidity¹.
The pathophysiology of this syndrome is autoimmune driven due to the presence of antibodies against Glutamic Acid Decarboxylase (GAD), the rate-limiting enzyme for synthesising γ-Aminobutyric Acid (GABA) in cerebrospinal fluid of SPS patients.
We encountered an interesting case of a 52-year-old Japanese lady with underlying ‘Stiff Person Syndrome (SPS)” scheduled for day-case upper gastrointestinal endoscopy and colonoscopy. She was diagnosed with SPS in 2018 with Hashimoto Thyroiditis and chronic headache. She takes Baclofen, Myonal, Paracetamol and Celebrex for her SPS and Euthyroxin for hypothyroidism. Her manifestation of SPS was usually painful spasticity of her limbs triggered by anxiety or pain stimuli.
We successfully managed her case with monitored anaesthesia care throughout the procedure. The approach mainly focused on ensuring adequate depth of sedation and avoiding her triggering factors (anxiety and pain). First, she was given a local anaesthesia spray before cannulation in a calm environment. Next, midazolam of 2mg was given intravenously. Next, we maintained her sedation with target-controlled infusion (TCI) Propofol of 1.5mcg/ml. Finally, an intravenous bolus of 25mcg Fentanyl was given before the surgeon performed a colonoscopy.
She went through both upper and lower GI scopes without spasms or rigidity. She remained pain-free and asymptomatic in the recovery bay and was discharged home the same day.
A literature search revealed several case reports on the anaesthetic management of SPS patients (Table 1).

Reference Procedure Anaesthesia Method  Drugs Outcome
Johnson & Miller⁵ Repair of Baclofen pump GA, volatile, muscle relaxant Sufentanil, Thiopentone, Vecuronium,Isoflurane, N20, Neostigmine/Glycopyrolate Mechanical ventilated overnight. Muscle  strength recovered post-op day 2
Johnson & Miller⁵ Same procedure GA, volatile agent. No muscle relaxant Midazolam, Halothane, Isoflurane, N20 Uneventful
Haslam & Price⁶ Respiratory failure GA with muscle relaxant Midazolam, Propofol, Atracurium, Fentanyl Uneventful
Haslam & Price⁶ Same procedure GA with muscle relaxant Alfentanil, propofol, Atracurium Uneventful
Obara et al⁷ Thymectomy GA, volatile agent, muscle relaxant Fentanyl, Thiopentone, Vecuronium, Isuflurane, N20 Uneventful
Obara et al⁷ Appendicectomy GA, volatile agent, muscle relaxant Diazepam, Fentanyl, Thiopentone, Vecoronium, Isoflurane, N20 Uneventful
Obara et al⁷ Endoscopic nasal surgery GA, muscle relaxant Fentanyl, Propofol, Vecuronium, N20 Clinical symptoms improved after anaesthesia
Bouw et al⁸ Resection of colon carcinoma GA, volatile agent, muscle relaxant Propofol, Sufentanil, Atracurium, Isoflurane, Morphine, Neostigmine/Glycopyrolate Patient could not open eyes with weak grasp. Mechanical ventilated for 1 hour post-op
Elkassabany et al⁴ Inguinal hernia repair Regional (paravertebral block),monitored sedation Bupivacaine, Midazolam, Fentanyl, Propofol Improvement in symptoms during procedure and 1 hour post op.
Ledowski & Russell³ ENT surgery GA, TIVA


Propofol, Remifentanyl, Morphine Uneventful
Qin et al⁹ Thymectomy GA, volatile agent, muscle relaxant Midazolam, Propofol, Remifentanyl, N20, Rocuronium, Isoflurane Uneventful
Yamamoto et al² Thymectomy GA, volatile agent. No muscle relaxant Fentanyl, Propofol, Sevoflurane, Remifentanyl Uneventful
Shanthanna et al¹⁰ Bilateral knee amputation Combined spinal epidural Midazolam, Bupivacaine, Fentanyl Epidural analgesia required 3 days post-op

The common triggers for spasms are sudden loud noises, stress, anxiety and pain stimuli. The challenges faced by anaesthetists in SPS patients are avoiding trigger factors for cramps and the type of anaesthesia to be given to the patient to prevent prolonged hypotonia after surgery. Therefore, it is essential to learn from the literature to safely and successfully manage SPS patients for surgery.
Several case reports have been published on the successful management of SPS patients in surgery without complication. Most successful cases were done under regional/spinal anaesthesia or general anaesthesia with total intravenous anaesthesia (TIVA). For example, Yamamoto K et al. combined general and epidural anaesthesia for their patient undergone thymectomy². Using an epidural is beneficial for superior pain management and reduces the impact of anaesthesia with GABAergic action. However, if general anaesthesia is required for surgery, total intravenous anaesthesia (TIVA) is excellent to conventional general anaesthesia with a volatile agent and muscle relaxant³.
Spinal and regional anaesthesia is advocated to be the best choice if deemed appropriate for surgery. Elkassabany et al. performed a paravertebral block with conscious sedation for their SPS patient who had undergone inguinal hernia repair successfully⁴. However, this method can be challenging due to the risk of spasms induced by pain during needle entry or anxiety from situation awareness.
In our case, we successfully managed our patient with monitored anaesthetic sedation (TCI Propofol) with a combination of anxiolytic (Midazolam) and analgesia (Fentanyl).
Muscle relaxants have been previously thought to cause prolonged hypotonia in SPS patients. Johnson & Miller first reported that their patient had extended hypotonia with Vecuronium use leading to 48 hours of invasive ventilation despite the adequate reversal of the muscle relaxant⁵. The avoidance of Vecuronium use resulted in uneventful second surgery for the same patient⁵. This sparks controversial debate because it was not reported by Haslam & Price with the help of Atracurium in their patient on two separate occasions⁶. The antibodies GAD responsible for SPS does not affect neuromuscular junction; therefore, muscle relaxant should not cause prolonged weakness. Obara et al. objectively assessed the block depth with a train of four (TOF) ratio in SPS patients. When neuromuscular monitoring was used during the case, it demonstrated recovery of the march of four proportions (TOF) to 100% post-operation, suggesting that muscle relaxation has no effects in SPS patient⁷.
Bouw et al. later attribute the observation reported by Johnson & Miller to the effects of the volatile agent rather than muscle relaxant in a patient on Baclofen treatment. The majority of patients are taking Baclofen as a treatment before surgery⁸. The presence of Baclofen will amplify the GABA (b)-ergic effects of the volatile agent. This might be dose-related, and the result was not apparent if a lower volatile agent concentration was used. Qin et al., who use a lower concentration of Isoflurane (0.2-0.4%) along with Nitrous Oxide and Remifentanyl infusion, found no complication in their patient⁹.
In conclusion, SPS is a debilitating condition for the patient and a challenging task for anaesthesiologists during surgery. However, with careful consideration of the best modality of anaesthesia for the patients, ensuring a calm and quiet environment, patients will have a good outcome of surgery without any complications.
*Consent obtained from the patient for publication of case report.

MOERSCH FP, WOLTMAN HW. Proc Staff Meet Mayo Clin. 1956 Jul 25; 31(15):421-7
Yamamoto K, Hara K, Horishita. J Anesth 21: 490-492. 2007
Ledowski T, Russell P. Anaesthesia 61(7): 725. 2006
Elkassabany N, Tetzlaff JE et al. J Clin Anesth 18(3): 218-220. 2005
Johnson JO, Miller KA. Anesth Analg 80: 612-613. 1995
Haslam N, Price K. Anaesthesia 57: 298-299. 2002
Obara M, Chinzei M, Komatsu K et al. Anaesthesia 57: 511. 2002
Bouw J, Leendertse K, Tijssen MA. Anesth Analg 97: 486-487. 2003
Qin X, Wang D, Wu X. Chin Med J 119(11): 963-965. 2006
Shanthanna H. J Anaesth Clin Pharmacol 26(4): 547-548. 2010

[maxbutton id=”1″ url=”https://www.esaic.org/newsletter/” text=”Read the Newsletter” ]